#1Addressing the leading causes of blindness in the developed world Nova Eye Medical Limited (ASX:EYE) Capital Raising Presentation February 2024#2Important Notice and Disclaimer This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE) (Nova Eye or Company). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estimates, opinions or other information contained in the presentation. The information in this presentation is of a general nature and does not purport to be complete nor does it contain all information which a prospective investor may require in evaluating a possible investment in Nova Eye or that would be required in a prospectus, or a product disclosure statement prepared in accordance with the requirements of the Corporations Act. Future performance This presentation may contain forward looking statements. These forward-looking statements have been made based upon Nova Eye's expectations, assumptions and beliefs concerning future developments and their potential effect on Nova Eye (and its controlled entities), based on information currently available to management as at the date of this presentation. These forward- looking statements are subject to risks, stakeholder engagement, assumptions and uncertainty which are, in many instances, beyond Nova Eye's control. Further information regarding the key risks associated with investment are located on slides 34-40 of this presentation and you should consider these risks carefully. While Nova Eye believes that the expectations reflected in the forward-looking statements in this presentation are reasonable, neither Nova Eye not its directors or any other person named in the presentation can assure you that such expectations will prove to be correct or that implied results will be achieved. These forward- looking statements do not constitute any representation as to future performance and should not be relied upon as financial advice of any nature. Any forward-looking statement contained in this document is qualified by this cautionary statement. Not an offer This presentation does not constitute an offer to sell or a solicitation or an offer to purchase any security or financial product or service and is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. Not financial product advice This presentation does not constitute financial product or investment advice or any recommendation to acquire new shares or accounting, legal or tax advice. It has been prepared without taking into account the objectives, financial or tax situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial and tax situation and needs and obtain legal and taxation advice appropriate to their jurisdiction. Disclaimer To the maximum extent permitted by law, neither Nova Eye nor its related bodies corporate, directors, officers, employees or agents, nor any other person, accepts any liability, including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it. Nova Eye is under no obligation to release any updates or revisions to tis presentation to reflect any change in expectation or assumptions and disclaim all responsibility and liability for these forward-looking statements (including, without limitation, liability for fraud or negligence). pupil suspensory ligament iris anterior chamber cornea lens sclera lateral rectus muscle medial rectus muscle choroid vitreous body retina ne macula lutea fovea centralis (central depression) optic nerve optic disc (blind spot) nova-eye.com | 2#3Executive Summary 01 Following FDA clearance on March 30, 2023, and subsequent USA launch of the iTrack™ Advance in May 2023, Nova Eye Medical Limited (Nova Eye) has driven USA glaucoma sales revenue to US$5.1m for 1H FY24, up 65% on pcp, selling through its own sales team direct to US eye surgeons 02 Glaucoma products sales growth in the first half of FY24 was achieved despite market uncertainty during November and December arising from proposed changes to reimbursement tabled by Medicare Administrative Contractors (MACS) to restrict reimbursement coverage. The proposed changes were withdrawn on 29 December 2023 enabling future sales growth 03 Nova Eye sees significant near and medium-term opportunities to expand our glaucoma geographic sales footprint across the USA, alongside strategic international markets. Focused product development and clinical evidence collation across the Glaucoma portfolio will de-risk the Company from reimbursement changes 04 Announcement of capital raising of $8.0 million to capitalise on identified near-term growth opportunities in Glaucoma n nova-eye.com | 3#4re Nova Eye Medical Company Overview#5Large Unmet Need Glaucoma Opportunity ne 126 million (1) people with glaucoma worldwide with US$5.6 billion (1) annual expenditure of which 78% (1) is spent on medications and devices. Market for surgical devices is US$743 million (2) and forecast to reach US$1,341 (2) million by 2028 Significant medication drawbacks drive demand for surgical device alternatives Consumable surgical devices market projected market at 15% CAGR (2) (1) Marketscope 2023 Glaucoma Surgical Device Market Report and Marketscope 2022 Glaucoma Surgical Device Market Report (2) Marketscope 2023 Glaucoma Surgical Device Market Report, 2024 estimate and 2028 estimate incorporating stents, canal surgery and glaucoma drainage devices, growth through to 2028 nova-eye.com | 5#6Business Segment Overview ne Strategy Key products Total Addressable Market Sales Manufacturing Nova Eye Medical, Glaucoma Develop, market and sell comprehensive portfolio of glaucoma consumable surgical devices iTrack™ Advance, iTrack TM, Molteno3, US$743m(1) with the glaucoma surgical devices market growing at 15% CAGR over 2022-28(1) displacing medication Established infrastructure; direct sales in USA, Germany, Australia; distributors in key markets California, USA and Dunedin, New Zealand IP Status Patents issued and pending in major markets Regulatory Reimbursement Europe and Mutual Recognition Jurisdiction and USA (FDA) Reimbursed by USA Medicare Strategy Key products Total Addressable Market Sales Manufacturing IP Status Regulatory Structure AlphaRET, AMD Commercialise unique and proprietary technology that addresses AMD with funding from a partner 2RT 62 million (2) people worldwide with Intermediate Age- related Macular Degeneration treatment (iAMD) – market not addressed. Sales program to coincide with funding Adelaide, Australia based contract manufacturing Patents issued and pending in major markets CE Mark (iAMD) and diabetic eye disease) in Europe, Australia, NZ. FDA USA clearance for diabetic eye disease AlphaRET is a wholly-owned subsidiary of Nova Eye Medical Limited. (1) Marketscope 2023 Glaucoma Surgical Device Market Report, 2024 estimate incorporating stents, canal surgery and glaucoma drainage devices, growth through to 2028 (2) Estimate made by Nova Eye based on the results of clinical studies and Marketscope 2022 Ophthalmic Lasers Market Report, 2024 estimate nova-eye.com | 6#7Addressing disease progression re iTrack™ Advance (mild to moderate) iTrack™ (mid stage) G Molteno3 (Severe and Complex) Glaucoma Nova Eye Current Product Portfolio nova-eye.com | 7#8Glaucoma Disease Overview ne • Glaucoma is the second leading cause of blindness in the developed world (behind cataracts) (1) Progressive, irreversible eye disease that causes vision loss due to optic nerve damage from elevated intraocular pressure (IOP). There is no cure for glaucoma. Topical medications are standard of care but nonadherence is ubiquitous Nova Eye's products reduce IOP via surgical procedures 1 1. Drainage canal becomes blocked; too much fluid stays in the eye and IOP rises. PRESSURE 2 2. High IOP damages optic nerve, leading to blindness (1) Marketscope 2023 Glaucoma Surgical Device Market Report nova-eye.com | 8#9Glaucoma Treatment Overview Traditional medication treatment paradigm is chronic medication use causes eye damage limiting future treatment options. Patients and surgeons are transitioning (1) from medications in favour of minimally invasive glaucoma surgery (MIGS) earlier in the disease state. MIGS are a solution to nonadherence and can offer improved safety profile and better certainty of outcome (1). Advancements in diagnostic technologies support earlier intervention. Nova Eye is a key player in the global MIGS market with its canaloplasty device, iTrack™ Advance. (1) Marketscope 2023 Glaucoma Surgical Device Market Report and Marketscope 2022 Glaucoma Surgical Device Market Report •EEEE Patient adherence to glaucoma medications is poor يع Approx 50% of patients are non-compliant with their medications Approx 50% purposely discontinue their medication(s) within 6 months Nordstrom BL, Friedman DS, Mozaffari E, Quigley H, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140(4): 598-606 Glaucoma surgical devices are increasingly recognised as a viable alternative to medications - and this is the highest area of focus and return for the patient, the physician and the supplier. nova-eye.com | 9#10TM iTrack™ ADVANCE (1) Based on Nova Eye's sales records • • · • iTrack™ Advance consumable MIGS device is redefining the treatment of glaucoma in its early stages. Canaloplasty offers a stent-free, tissue-preserving surgical treatment for glaucoma using an injector technology Injector technology has enhanced our original iTrack™ which has been used in approx. 130,000 (1) procedures globally. Approved by the FDA on 30 March 2023 and launched in the USA May 2023 nova-eye.com | 10#11Clinically Significant Features iTrack TM Advance vs Other MIGS Designed to reduce the elevated IOP associated with glaucoma by improving trabecular flow through the natural outflow pathway. Device Company Procedure iTrack T Advance Nova Eye Medical Canaloplasty KDB(1) New World Medical Goniotomy OMNI(1) Sight Sciences Patient Population Natural Outflow Pathway Implant- Preserves free Tissue Trabecular Meshwork Schlemm's canal Collector Channels Mild-moderate glaucoma Mild-moderate i.e. cutting of tissue Canaloplasty followed by goniotomy i.e. cutting of tissue glaucoma Mild-moderate glaucoma Mild-moderate iStent(1) Micro-trabecular Glaukos bypass stent Hydrus(1) Micro-trabecular glaucoma Mild-moderate Alcon bypass stent glaucoma (1) Based on collation of information in Marketscope 2023 Glaucoma Surgical Device Market Report and company information on websites X × × X Х х × nova-eye.com | 11#12USA Sales Growth Opportunity, iTrack" Advance TM • Nova Eye's direct-to-surgeon sales channel is driving growth of iTrack™ • A Active Accounts, Glaucoma (x200) B Inactive Accounts, Glaucoma (x300) Advance, Nova Eye's flagship product. Recruitment of additional sales representatives drives new account acquisition through improved geographical coverage Additional marketing and clinical support drives surgeon re-order rates and enhances product introduction A B Active Accounts, Glaucoma | approx. 200 accounts Successfully transitioned existing iTrack™ customer accounts TM to iTrack Advance during May-June 2023. Inactive Accounts, Glaucoma | approx. 300 accounts Reactivation of inactive customer accounts commenced in July 2023 is continuing through FY24. ΤΜ iTrack™ ADVANCE (market opportunity) C New Accounts, Glaucoma D 1) 2) Potentially 1200(1) accounts available for sales growth via new glaucoma surgeon accounts New Accounts, Cataract and Comprehensive Potentially 9000 (2) accounts available for sales growth via new cataract and comprehensive surgeon accounts 2,364 glaucoma specialists per Marketscope 2023 Glaucoma Surgical Device Market Report. An account can have more than one glaucoma surgeon. Management estimates that this equates to between 900 and 2000 accounts. An estimate of 1200 has been made based on a ratio of two per account 11,238 cataract surgeons per Marketscope 2023 Glaucoma Surgical Device Market Report. An account can have more than one cataract surgeon. Management estimates that this equates to between 6000 and 11000 accounts. An estimate of 9000 has been made. D New Accounts, Cataract and Comprehensive (x9000) C New Accounts, Glaucoma (x1200) nova-eye.com | 12#13Glaucoma Device Sales in USA and outlook • . US$5.1m (1) sales for the 6 months to 31 December 2023 (65% growth) despite sales in November and December 2023 negatively impacted by the uncertainty of proposed reimbursement changes that were announced on 31 October 2023. Uncertainty resolved on 29 December 2023 restoring surgeon purchasing confidence. Since its USA launch in May 2023 the iTrack™ Advance has demonstrated a steady increase in demand from ophthalmologist customers. With reimbursement uncertainty resolved, Nova Eye expects USA sales growth to accelerate. January 2024 sales are up approximately 54% against January 2023 and in line with December 2023 as customers are educated on the resolution of the proposed reimbursement changes and Christmas and New Year holidays impact purchasing cycles. USA sales since launch of iTrack TM Advance Pre reimbursement uncertainty During reimbursement uncertainty no Significant month-on-month sales growth post USA launch of iTrack Advance (74% for the 4 months to 31 October 2023 compared with pcp) (1) 1H FY24 sales up 65% pcp(1) I (1) Unaudited sales based on Company financial records Refer to details in Appendix A 0 Apr-23 May-23 Jun-23 Jul-23 Aug-23 Sep-23 Oct-23 Nov-23 Dec-23 nova-eye.com | 13#14Growth Opportunities Outside of the USA • • • no During H1FY24 Nova Eye has invested in market access in key territories outside the USA. New investment in sales infrastructure offers growth opportunities. Western Europe and Canada markets with product registrations, reimbursement and sales channel in place: Germany (via hybrid direct and distributor channel), UK (iTrack TM Advance NHS and NICE approved), Spain, Italy, Poland, Switzerland, UAE and Canada (via hybrid direct and distributor channel) - China approvals in place, approval iTrack TM Advance pending. Established distributor with early market penetration temporarily disrupted in 2023 by medical industry-wide government review of marketing methods. South Korea - sales channel in place and registration for iTrack TM Advance pending. Singapore - Hybrid direct and distributor sales channel. Singapore is an important reference market in driving procedural adoption throughout South-East Asia. Market access work complete; these markets offer growth opportunities USA Scale existing commercial infrastructure for growth Growth Market The glaucoma surgical device market in Western Europe is expected to grow at a CAGR of 16% to 2028 and is currently valued at US$114m per annum(¹). (1) Marketscope 2023 Glaucoma Surgical Device Market Report, 2024 estimate and 2028 estimate incorporating stents, canal surgery and glaucoma drainage devices, growth through to 2028 Western Europe New iTrack Advance registration pending South Korea New iTrack Advance registration pending China iTrack Advance registration Singapore completed April 2023 nova-eye.com | 14#15H1 FY24 Global Sales no H1 FY23 (Audited) H2 FY23 FY23 (Audited) H1 FY24 (unaudited) Growth on PCP US Dollars '000's USA Western Europe 3,060 3,587 6,647 5,050 65% 1,331 1,252 2,583 1,255 -6% Western Europe OEM sale of equipment (1) China 256 - 256 N/A 1,050 736 1,786 315 -70% Total 5,697 5,575 11,272 6,620 16% Focus of sales and marketing investment in USA following launch of iTrack™ Advance in May 2023 with demonstrated growth results. Investments in marketing outside the USA have been limited. Western European iTrack™ sales have fallen 6% in 1H FY24 compared to the PCP reflecting the limited sales and marketing investment in this region (focus on USA). Sales to China temporarily disrupted in 2023 by medical industry-wide government review of marketing methods. PCP was impacted by a delivery of previous order scheduled for 30 June 2022 delivery delayed export documentation until 5 July 2022. (1) Sales in Germany and Europe in the PCP included a OEM sale of a package of iLumin light sources nova-eye.com | 15#16ع ng Glaucoma Product Portfolio and Disease State Portfolio of glaucoma technologies addressing different stages of the disease PROGRAM STATUS STAGE OF GLAUCOMA MILD GLAUCOMA MODERATE GLAUCOMA SEVERE GLAUCOMA COMPLEX GLAUCOMA COMMERCIAL iTrack™ ADVANCE Canaloplasty device injector deployed by comprehensive ophthalmologist in conjunction with cataract surgery. iTrack™ ADVANCE Canaloplasty device injector deployed by glaucoma specialist as standalone procedure - restores trabecular flow. iTrack™ Canaloplasty manually deployed by glaucoma specialist with scleral surgery and/or suture- restores trabecular flow. Molteno3Ⓡ Glaucoma drainage device deployed by glaucoma specialist - drainage device bypassing trabecular flow. Product development opportunities Severe and complex glaucoma is an underserved segment. Product range to cater to the preferences of eye surgeons treating broader range of patients with expansion of reimbursement codes. nova-eye.com | 16#17Glaucoma Device Product development Expanding product portfolio leveraging existing IP to expand range of device surgeries covered by reimbursement codes ع ne Extend product range to cater to the preferences of eye surgeons treating broader range of patients. • iTrack™ Advance product enhancements for "Next Gen" trabeculotomy product. Low risk regulatory pathway in USA determined • Stable need for trabeculotomy with well-established reimbursement code. Glaucoma surgical devices segment Global market size 2024 (US$ m)(1) Nova Eye Product Canal surgery devices and stents $634m iTrack TM product suite GDD segment (aka "Tube Shunts")(1) $108m MoltenoⓇ product suite Severe and complex glaucoma is an underserved segment. Molteno3® product enhancements for Molteno "Next Gen" glaucoma drainage device (GDD) segment. Low risk regulatory pathway in USA determined • Stable need for GDD's with well-established reimbursement code (Progress on Molteno "Next Gen" is subject to cash generated from sales growth) Total $742m (1) Marketscope 2023 Glaucoma Surgical Device Market Report nova-eye.com | 17#18Strong Existing Clinical Data Set Underpins Surgeon Adoption ne Recent Peer Review Data Publication Consistency in Standalone Canaloplasty Outcomes Using the iTrack Microcatheter Authors Journal Khaimi, M (USA, Gallardo M (USA) and Korber N (Germany). Clinical Ophthalmology, 2024. Clinical outcomes of canaloplasty via an ab- interno surgical technique using the iTrack device: a narrative review 6-Year Efficacy and Safety of iTrack Ab- interno Canaloplasty as a Standalone Procedure and Combined with Cataract Surgery in Primary Open- Angle and Pseudoexfoliative Glaucoma Long-Term Clinical and Safety Outcomes of Canaloplasty Performed across All Grades of Glaucoma Severity Surgical Management of Intraocular Pressure With Ab-interno Canaloplasty in Postkeratoplasty Patients: 12-Month Results Koerber N (Germany), Ondrejka S (Germany). Koerber N (Germany), Ondrejka S (Germany). International Ophthalmology, . 2023. Journal of Ophthalmology, 2023. Journal of Ophthalmology, Patel S (USA), Reiss G (USA). 2023. . • • • Riaz KM et al (USA). Cornea, 2023. • Data Overview Multicenter, multi-surgeon, retrospective review of a consecutive case series At 12 months, IOP (mmHg) was reduced in 57 of the 58 (98%) remaining eyes; one eye had the same IOP with a reduced number of medications. Nine studies which totalled 365 eyes. At 12 and 24 months, IOP (mmHg) decreased from 20.0±2.5 preoperatively to 13.8±0.6 and 14.0±0.9. Single-center retrospective case series of patients (n=27 eyes) followed for up to 6 years. The mean IOP was reduced significantly from 19.9±5.2 mmHg (n=27) at baseline (no washout) to 14.6±3.3 mmHg at the 6-year follow-up (n=18; p<0.001). Single-center, retrospective case series study of glaucoma eyes (n=72) with mild- moderate glaucoma as compared to severe glaucoma. The mean preoperative IOP for the 72 eyes was 18.6±5.8 mmHg, which showed a 25% reduction to 13.5±4.7 mmHg at 36 months (p<0.001). Single-center, retrospective case series of postkeratoplasty eyes(n=17) undergoing ab- interno canaloplasty (ABIC). ABIC effectively reduced IOP and maintained graft survivability in postkeratoplasty eyes for at least 12 months. nova-eye.com | 18#19Program of Data Collection Continuing ريع Clinical Study Program - additional data collation de-risks exposure to future reimbursement changes Study Name Study Type Study Sites Study Details iTrack TM Global Data Registry WCG IRB (approval number) 20200728 Prospective, multicenter, real-world registry study 20+ sites in the USA, UK, Canada, Australia, Singapore and Germany. • • 350+ patient data entries completed since mid 2022 All glaucoma severities i.e., mild, moderate and severe Study Synopsis • Independent cloud-based platform that collates efficacy and safety data for the canaloplasty procedure (iTrack TM and iTrack TM Advance) Hosted in collaboration with the International Glaucoma Surgery Registry (IGSR), the official registry partner of the European Glaucoma Society (EGS). Prospective, multicenter randomised control CATALYST Study NCT05564091 trial. MAGIC Study (Europe) NCT05786196 5+ sites in Germany, • 140 patients in total (recruitment ongoing) Mild-moderate glaucoma Canaloplasty performed in combination with cataract surgery "Cataract Surgery in Conjunction with Canaloplasty via an Ab- Interno Approach in Patients with Mild to Moderate Primary Open-Angle Glaucoma" Comparison of iTrack TM Advance performed in combination with cataract surgery, compared to cataract surgery alone. . the Netherlands and Australia Prospective, multicenter randomised control trial. 5+ sites in the UK, Italy, Spain and Germany. • 78 patients in total (recruitment ongoing) • Mild-moderate glaucoma • Canaloplasty performed as a standalone procedure Multicenter Glaucoma Study Investigating Standalone Canaloplasty Comparison of the iTrack TM Advance as compared to the OMNIⓇ Surgical System (Sight Sciences). nova-eye.com | 19#20re Offer Details#21Offer Summary na g Nova Eye is seeking to raise approximately A$[8.0] million via the issue of approximately [38.1] million new fully paid ordinary shares ("New Shares") An institutional Placement to raise up to approximately A$[3.0] million ("Placement") • A 1 for [8.0] pro-rata accelerated non-renounceable entitlement offer ("ANREO") to raise approximately A$[5.0] million ("Entitlement Offer") (together, the "Equity Raising" or "Offer") The Equity Raising will be conducted at A$[0.210] per New Share representing a: • Offer structure and size • Offer Price [23.6]% discount to the last traded price of $[0.275] on [09 February 2024] • [24.2]% discount to the 10-day VWAP price of $[0.277] . [20.5]% discount to TERP of $[0.264] Use of Proceeds Placement and Institutional Entitlement Offer Retail Entitlement Offer Ranking Bookrunner Joint Lead Managers Proceeds from the Equity Raising will be used to advance near-term growth opportunities across Nova Eye's Glaucoma business, including expanding the geographical presence of iTrack TM Advance sales in the US and Europe, and to broaden the product portfolio in Glaucoma surgical devices. The Placement and the Institutional component of the Entitlement Offer (Institutional Entitlement Offer) will be conducted by way of a bookbuild process from [9am] [Monday, 12 February 2024] to [12pm] [Tuesday, 13 February 2024]. Entitlements under the Institutional Entitlement Offer that are not taken-up, entitlements of ineligible institutional shareholders and ineligible retail shareholders under the Entitlement Offer will also be sold in the bookbuild process. The Record date for the Retail component of the Entitlement Offer ("Retail Entitlement Offer") is 7.00pm [Wednesday, 14 February 2024]. The Retail Entitlement Offer will open on [Monday, 19 February 2024] and close on [Friday, 08 March 2024] Each New Share issued under the Equity Raising will rank equally with existing fully paid ordinary shares on issue E&P Corporate Advisory E&P Corporate Advisory, MST Financial, Taylor Collison nova-eye.com | 21#221) 2) Use of Proceeds $3.7m Glaucoma Surgical Devices:$7.0m USA sales growth - USA sales representative expansion, marketing and clinical data program enhancement $1.6m Outside USA sales growth - Expand commercial infrastructure in prospective markets to leverage investment in market access $1.7m Broaden product portfolio and regulatory approvals to de-risk reimbursement changes (1) Other Costs: $0.5m $0.5m MDR(2) compliance and working capital Offer Costs: $0.5m $0.5m Costs of the Offer Total: $8.0m iTrack Next Gen only. Molteno Next Gen investment subject to cash generated from operations Medical Device Regulation in Europe nova-eye.com | 22#23Indicative Offer Timetable ne Item Trading Halt and announcement of the Equity Raising, lodgement of Offer Documents Institutional Placement and Institutional Entitlement Offer opens Institutional Placement and Institutional Entitlement Offer closes Date [Monday, 12 February 2024] [9am, Monday, 12 February 2024] [12pm, Tuesday, 13 February 2024] Announcement of completion of the Institutional Entitlement offer, trading halt lifted, existing securities recommence trading [Wednesday, 14 February 2024] Record Date for Retail Entitlement Offer (7pm) Retail Entitlement Offer opens Allotment of New Shares issued under the Institutional Entitlement Offer and Placement Retail Entitlement Offer closes Announcement of results of the Retail Entitlement Offer and notification of any shortfall Allotment and issue of New Shares under the Retail Entitlement Offer Trading commences on a normal basis for New Shares issued under the Retail Entitlement Offer [Wednesday, 14 February 2024] [Monday, 19 February 2024] [Thursday, 22 February 2024] [Friday, 08 March 2024] [Friday, 15 March 2024] [Friday, 15 March 2024] [Monday, 18 March 2024] nova-eye.com | 23#24Operating Results for H1FY24 FY23 (Audited) H1 FY24 (unaudited) Australian dollars ('000'S) Group Revenue Glaucoma AlphaRET Corporate Group Glaucoma AlphaRET Corporate Group 16,661 364 17,025 10,062 77 10,139 GM 11,392 323 11,715 6,900 40 6,940 68% 69% Operating (17,676) (1,364) (2,225) (21,265) (9,433) (473) (1,213) (11,119) expenditure EBITDA (loss) (6,284) (1,041) (2,225) (9,550) (2,533) (433) (1,213) (4,179) FY23 (Audited) H1 FY24 (unaudited) Glaucoma only USA dollars ('000's) Commentary on H1FY24 compared with FY23 • Improved gross margin Improved ratio of operating expenditure to revenue shows leverage Revenue GM 11,273 6,619 7,548 4,539 67% 69% Operating (11,548) (6,128) expenditure EBITDA (4,000) (1,589) ne nova-eye.com | 24#25Balance Sheet at 31 December 2023 31 December 2023 (unaudited) $'000's 30 June 2023 (audited) $'000's ع no 31 December 2023 (unaudited) $'000's 30 June 2023 (audited) $'000's Current liabilities Current assets Trade and other payables 4,149 4,311 Cash and cash equivalents 2,612 7,419 Borrowings and lease obligations 714 639 Trade and other receivables 2,204 2,221 Provisions 1,458 1,324 Income tax refund receivable 0 884 Total current liabilities 6,328 6,274 Inventories 4,131 3,806 Non-current liabilities Prepayments 284 270 Borrowings and lease obligations 500 892 Total current assets 9,231 14,600 Deferred tax liability Non-current assets Total non-current liabilities 500 892 Total liabilities 6,821 7,166 Trade and other receivables 70 71 Net assets 17,052 23,191 Property, plant and equipment 932 965 Equity Lease right-of-use asset 1,097 1,397 Issued capital 45,294 45,175 Intangible assets 7,986 8,454 Reserves (215) (87) Capitalised development expenditure 4,558 4,870 Accumulated (losses) / profits (28,028) (21,897) Total non-current assets 14,642 15,757 Total equity 17,052 23,191 Total assets 23,873 30,357 nova-eye.com | 25#26Development Milestones 2024 ne Nova Eye is addressing large unmet needs and has a plan in place to grow the glaucoma business Glaucoma Segment • USA sales growth acceleration • • Sales growth in markets outside the USA Targeting cash flow break even by FY25 • New product introduction nova-eye.com | 26#27re Appendix A Additional materials#28Nova Eye Glaucoma Surgical Device Reimbursement Transaction in USA Illi Eye surgeon selects Nova Eye product Nova Eye delivers the product to the Facility and invoices the Facility. The operating notes are submitted to Medicare Administrative Contractor (MAC) responsible for that geographic area (1) # = $ + Eye surgeon operates in a facility which is either a Hospital (HOPD) or an Ambulatory Surgery Centre (ASC) and advises purchasing department to issue an order to Nova Eye for the product (1) Medicare for patients older than 65-years, certain private payors for other patients (2) Center for Medicare and Medicaid Services Eye surgeon conducts the surgery. CMS (2) reimbursement code specified in surgery operating notes. The MAC will pay the claim on behalf of CMS in two parts; a payment to the Facility ( fee to either HOPD or ASC) and a payment to the eye surgeon (Physician Fee) nova-eye.com | 28#29Reimbursement for Nova Eye Products in the USA Product Facility Fee for applicable surgery for 2024 (US$) Physician Fee for applicable surgery for 2024 (US$) HOPD ASC iTrack Advance for canaloplasty surgery $3,877 $2,045 $607 Molteno3 Glaucoma Drainage device $2,222 $1,183 $828 • Fees set and reviewed annually by CMS • Differential product pricing to HOPD and ASC • • Nova Eye invoices the Facility and the product price is paid from the Facility fee Payments against a particular CMS code by MACs can change from time to time. with the issue of a new "Local Coverage Determination (LCD)" ne nova-eye.com | 29#30Recent Developments in USA Reimbursement Five MACS table draft local coverage determinations¹. (LCD) proposing changes to reimbursement for minimally invasive glaucoma surgeries (MIGS). On 31 October 2023 WPS issued a "final" LCD and on 9 November the other 4 MACS did the same. They are required to give 45 days' notice, making the effective date 23 December 2023. On 8 December 2023 the effective date of the LCDs was shifted to 29 January 2024. يع July 2023 Aug 2023 Sep 2023 Oct 2023 Nov 2023 Dec 2023 Jan 2024 An LCD is a determination made on coverage made that applies to the region for which the MAC is responsible. Among other changes, the final LCDs designated canaloplasty as "investigational" and would not be reimbursed. Nova Eye immediately activated near-term initiatives designed to overcome the challenges imposed by the proposed LCD changes to reduce the expected impact on sales revenue and provided support to doctors and professional bodies to lobby against the changes. On 29 December 2023, the LCDs were withdrawn and reimbursement for canaloplasty to continue unchanged. 1. In 2020, by Palmetto, issued a draft LCD and it was eventually with drawn without making it the "final". nova-eye.com | 30#31Who are the Medicare Administrative Contractors? • The MACS are private insurance . contractors granted responsibility by the US Government Center for Medicare and Medicaid Services (CMS) to administer the health care funding allocated by Congress • MACS administer claims, review doctors' operating notes, consider whether the surgery was medically necessary and pay the claims based on allowances (codes) provided by CMS MACs that proposed changes to Local Coverage Determinations (LCDs): • National Government Services (NGS) • . WPS Government Health Administrators (WPS) Palmetto GBA (Palmetto) • Celerian Group Company (CGS) Noridian Healthcare Solutions (Noridian) JE Noridian JF JF Noridian J6 NGS J8 WPS J5 WPS J15 CGS JL Novitas JH Novitas JJ Palmetto JM Palmetto JN FCSO ع ne JK NGS MACs that DID NOT propose changes to LCDs: • First Coast Service Options (FSCO) . Novitas Solutions (Novitas) nova-eye.com | 31#32re Appendix B Key Risks#33Key Risks - Specific no As with any share investment, there are risks associated with an investment in the Company. The numerous risk factors are both of a specific and general nature. Some risks can be mitigated by the use of safeguards and appropriate systems and controls, but some are outside the control of the Company and cannot be mitigated. Section 1 identifies and highlights some of the specific risks that potential investors should consider prior to acquiring shares in the Company. However, the following is not, and does not purport to be, a comprehensive statement of all relevant risks and is not listed in order of importance. Potential investors should seek their own financial or other professional advice in relation to the risks and must make their own assessment regarding an investment in the Company. 1 Specific Risks Business Strategy Execution Competition Risk Nova Eye's success will depend on its ability to successfully execute its business strategy. Nova Eye's future growth, profitability and cash flows depend on the ability of the Company's management to successfully execute its business strategy, which is dependent on a number of factors, including but not limited to its ability to: - develop its portfolio through new product development and market execution; - innovate and develop new products that are address consumer needs; - build and maintain sufficient supply to maintain service demand; - continue to expand its distribution channels to increase market presence, brand recognition and sales; - successfully expand into targeted international markets; - expand margins through sales growth and supply chain integration and efficiency initiatives; and - maintain disciplined capital management and working capital to improve the generation of cash flow. There is no guarantee that Nova Eye can successfully achieve any or all of the above initiatives or anticipated time frames. The failure of Nova Eye to execute its business strategy could have a material adverse effect on the Company's business, financial condition and results of operations. The innovative medical devices market is highly competitive. If Nova Eye can not compete effectively and competitors begin to produce comparable products and patient outcomes the Company's results could be negatively affected. Nova Eye competes on an international scale with companies around the world. Some competitors may have greater resources in comparison with Nova Eye and thus have the ability to respond more effectively to shifting business and economic conditions. Competition in the innovative medical devices market is based on functionality compared with existing treatments, pricing of products, quality of products and packaging, perceived value and quality of brands, innovation, promotional activities, advertising, editorials, and other activities. The actions of Nova Eye's competitors can not be predicted across the aforementioned areas or whether new competitors will emerge in the medical devices market, including competitors who offer comparable products at more attractive prices. In addition, further technological breakthroughs, new product offerings by competitors, and the strength and success of competitors' marketing programs may impede Nova Eye's growth and the implementation of its business strategy. In addition Nova Eye is dependent on the following factors to compete in its market: - the continued strength of its products and brands; - ongoing growth and innovation in Nova Eye's market segments; - the success of Nova Eye's branding, execution and integration strategies; - the successful management of new products; - successfully entering new markets and increasing penetration in existing geographies; and - its ability to protect the Company's intellectual property and utilise it to create value and support its business strategy. nova-eye.com | 33#34Key Risks - Specific Specific Risks (cont.) ne Product Safety and Liability Product safety or quality failures, actual or perceived, or allegations of product contamination, even when false or unfounded, may negatively impact Nova Eye's brands and could cause consumers to choose competing products. Allegations or adverse commentary on product safety or suitability for use by a particular consumer, even if untrue, may require Nova Eye to recall a product from all of the markets in which the affected product was distributed. Such issues or recalls could negatively affect Nova Eye's reputation and growth. If Nova Eye's products are perceived to be defective or unsafe, or if they otherwise fail to meet customer or regulators' expectations, the Company's relationships with customers could suffer, the appeal of one or more of its brands could be diminished, and the Company could lose sales or become subject to liability claims. In addition, safety or other defects in Nova Eyes competitors' products could reduce consumer demand for Nova Eye's products if consumers view them to be similar. Any of these outcomes could result in a material adverse effect on Nova Eye's business, financial condition and results of operations. Counterparty Risk Nova Eye is reliant on its main customers and suppliers. Inputs for Nova Eye's products consist of raw materials and packaging components and are purchased from various third party suppliers. The loss of multiple suppliers or a significant disruption or interruption in the supply chain could have a material adverse effect on Nova Eye's products. Increases in the costs of raw materials or other commodities may adversely affect the Company's profit margins if higher costs cannot be offset by price increases or lowering distribution costs. Nova Eye's third party suppliers pose risks to the Company if they do not comply with ethical, social, product, labour and environmental laws, regulations or standards, or their engage in politically or socially controversial conduct, such as animal testing, could negatively impact their reputations. Any of these failures or behaviours could lead to various adverse consequences, including damage to Nova Eye's reputation, decreased sales and consumer boycotts. Reliance on Key Customers There is a general risk that Nova Eye may fail to retain customers for a number of reasons, including pricing, competition or a failure to meet consumer expectations of its products. Reputational Risk Nova Eye's failure to protect its reputation, or the failure of the Company's partners to protect their reputations, could have a material adverse effect on the image of Nova Eye's brands. Nova Eye's ability to maintain its reputation is critical to the image and consumer perception of its various products. Nova Eye's reputation could be jeopardised if it fails to maintain high standards for product quality and integrity or if the Company, or the third parties with whom it does business, do not comply with regulations or accepted practices. Any consequential negative publicity may reduce demand for Nova Eye's products. Failure to comply with local laws and regulations, to maintain an effective system of internal controls or to provide accurate and timely financial information could damage Nova Eye's reputation. Nova Eye depends on the reputations of its third party clients, which can be affected by matters outside of the Company's control. Damage to Nova Eye's reputation or the reputations of its third-party clients could have a material adverse effect on Nova Eye's results of operations, financial condition and cash flows, as well as require additional resources to rebuild the Company's reputation. nova-eye.com | 34#35Key Risks - Specific Specific Risks (cont.) Business Disruption Growth Risk ne Nova Eye is engaged in developing, manufacturing and distributing innovative medical device devices for medical applications, utilising patented technology. As a result, Nova Eye is subject to the risks inherent in such activities, including industrial accidents, environmental events, strikes and other labour disputes, disruptions in supply chain or information systems, securing or maintaining adequate coverage or reimbursement by government or third-party payors for procedures using the iTrack®, the iTrack® Advance, Molteno 3Ⓡ, loss or impairment Nova Eye's product quality control, safety, licensing requirements and other regulatory issues, as well as natural disasters, pandemics, border disputes, acts of terrorism, and other external factors over which is out of Nova Eye's control. Should the Company's growth accelerate at a higher rate than anticipated, the Company may, through lack of availability of materials or packaging, inability to scale production in a timely manner, lack of manufacturing capacity, lack of suitable labour or other unforeseen circumstances, be unable to supply its products in a timely manner to meet the demand of its customers. Should this occur, the Company may risk the loss of either third party manufacturing clients or suffer a reduction in the customer base for its own products. Such events could have an adverse effect on both the reputation of the Company as well as its financial results. Reliance on Key Management Nova Eye, and each of its businesses, depend substantially on its key management, the loss of whose services might significantly delay or prevent the achievement of its business strategy. Nova Eye's ability to retain and attract qualified individuals is critical to its success. Nova Eye may not be able to attract, retain or replace suitable individuals currently or in the future on acceptable terms, or at all, and the failure to do so may adversely affect the Company. Access to Equity and Debt Funding Impairment of Intangibles Volatility in the financial markets could negatively affect Nova Eye's ability to raise capital through debt and equity raisings. Nova Eye's ability to raise additional funds will be subject to, among other things, factors beyond the control of the Company and its Directors, including cyclical factors affecting the economy and share markets generally. The Directors can give no assurance that Nova Eye can raise funds in the future on favourable terms, if at all. Nova Eye has intangible assets on its balance sheet relating intangible assets. Under the relevant accounting standards Nova Eye is required to annually test for impairment all indefinite life intangible assets. If this annual testing revealed that some or all of Nova Eye's intangible assets are impaired to a level below their carrying value, Nova Eye would be required to write down the value of those intangible assets. Such write downs could have a material adverse effect on Nova Eye's financial position. nova-eye.com | 35#36Key Risks – - - Specific ne Specific Risks (cont.) Health Insurance Reimbursement risk Regulatory and Legislative Risk Intellectual Property Infringement The Company derives revenue from sales of our products to physicians and surgery facilities, which typically bill all or a portion of the costs and fees associated with our products to various third-party payors, including Medicare and Medicaid in the USA, private commercial insurance companies, health maintenance organisations, and other healthcare-related organisations. Medical reimbursement systems vary significantly from country to country, with some countries limiting medical centres' spending through fixed budgets, regardless of levels of patient treatment, and other countries requiring application for, and approval of, government or third-party reimbursement. As a result, access to adequate coverage and reimbursement for procedures in which our products are used by third-party payors is essential to their acceptance and adoption by patients, facilities and physicians. These third- party payors continually review new and existing technologies for possible coverage and can deny or reverse coverage for new or existing products and procedures, and there can be no assurance that third-party payor policies provide coverage, or will continue to provide coverage, for procedures in which the Company's products are used. Nova Eye's business is subject to numerous laws and regulations in Australia and overseas. Changes in these laws and regulations, including their interpretation or enforcement, that affect, or will affect, the Company's business or products, including changes in accounting standards, tax laws and regulations, environmental or climate change laws, restrictions or requirements related to product content, labelling and packaging, regulations or accords, trade rules and customs regulations, could adversely affect Nova Eye's financial results. Failure adhere to various regulatory requirements and any regulatory action or enforcement may adversely affect Nova Eye's financial position. Obtaining and maintaining approvals from regulatory bodies or other third parties can involve significant time and expense, and delays in obtaining approvals or adapting to changes to laws and regulations may adversely impact Nova Eye's operations. Nova Eye's commercial success depends at least in part on its ability to operate without infringing, misappropriating or otherwise violating the trade marks, patents, copyrights and other proprietary rights of others. Nova Eye cannot be certain that the conduct of its business does not and will not infringe, misappropriate or otherwise violate such rights. As Nova Eye gains greater visibility and market exposure as a public company, third parties may allege that Nova Eye's products, services or activities infringe, misappropriate or otherwise violate their trade mark, patent, copyright or other proprietary rights in an attempt to gain a competitive advantage. Defending against allegations and litigation could be expensive, take significant time and divert management's attention. Nova Eye may also be required to pay substantial damages or be subject to court orders prohibiting the Company and its customers from selling certain products or engaging in certain activities. If Nova Eye operates its business in a way which infringes, misappropriates or otherwise violates the trade marks, patents, copyrights and proprietary rights of others, this could have a material adverse impact on the Company's business, financial condition and results of operations. Nova Eye's intellectual property is important to its success and any unauthorised use of any of the Company's intellectual property may result in the Company needing to commence litigation to protect those intellectual property rights which may incur significant costs. In addition, a failure to properly protect intellectual property rights may adversely affect the Company's business and reputation. There can be no assurances that the Company will be able to register or protect new intellectual property it develops in the future or prevent the unauthorised use of its intellectual property. nova-eye.com | 36#37Key Risks – - - Specific Specific Risks (cont.) Insurance Coverage ne Nova Eye has adequate levels of insurance to protect Nova Eye from potential losses and liabilities. There is a possibility that events may arise which are not adequately covered by existing insurance policies. In this case the Company may suffer adverse effects to its financial results as well as to the value of its brands. The Company cannot guarantee that its existing insurance will be available or offered in the future. An inability of the Company to secure such cover in the future could restrict the ability of the Company to conduct its business, and this could have a negative impact on the financial results of the Company. Unforeseen Expenditure Risk Nova Eye's future growth requires access to capital to fund its business strategy. Nova Eye expects that the proceeds from this Capital Raising will provide sufficient capital resources to enable Nova Eye to achieve its stated business strategy. In the event Nova Eye requires additional funding, there is no assurance that additional funding will be available on acceptable terms, if at all. Increased Input Costs Cost blow outs including but not limited to, labour, raw materials, freight, energy and key consumables could have a material impact on Nova Eye's operation and financial performance if these costs cannot offset. Foreign Exchange Rate Fluctuations Fluctuations in currency exchange rates may positively or negatively impact Nova Eye's financial position and operating results. Exchange rate fluctuations may affect Nova Eye's the input costs. The main currencies to which Nova Eye is exposed are the US Dollar, the Euro and the Australian Dollar. The exchange rates between these currencies in recent years have fluctuated significantly and may continue to do so in the future. A declining Australian Dollar will negatively affect Nova Eye's ongoing and future capital expenditure programs and may increase the costs of input materials. An appreciating Australian dollar may lead to a lower Australian dollar value for sales denominated in foreign currencies. nova-eye.com | 37#38Key Risks - General ع no Section 2 identifies and highlights some of the general risks that potential investors should consider prior to acquiring shares in the Company. However, the following is not, and does not purport to be, a comprehensive statement of all relevant risks and is not listed in order of importance. Potential investors should seek their own financial or other professional advice in relation to the risks and must make their own assessment regarding an investment in the Company General Risks Market and an Investment in Shares General Economic Conditions The market price of Nova Eye's shares will fluctuate due to various factors, many of which are non-specific to the Company, including the number of potential buyers or sellers of Nova Eye's shares on the ASX at any given time, recommendations by brokers and analysts, Australian and international general economic conditions, inflation rates, interest rates, changes in government, fiscal, monetary and regulatory policies, changes in law, fire, flooding, extreme weather events, natural disasters, global geo-political events and hostilities, acts of terrorism, state of emergency declarations, outbreaks of pandemics, outbreaks of war, and investor perceptions. These factors may cause Nova Eye shares to trade at a lower price than the Issue Price under the Placement. The trading price of Nova Eye shares may be adversely impacted by various factors, including new or changed governmental measures, business closures, lockdowns, quarantines, travel and other restrictions and resultant impacts on economies and financial markets. The historic share price performance of Nova Eye provides no guidance as to its future share price performance. Any deterioration in the domestic and global economy may have a material adverse effect on the performance of Nova Eye's business and Nova Eye's share price. It is possible that new risks might emerge as a result of Australian or global markets experiencing extreme stress, or existing risks, may manifest themselves in ways that are not currently foreseeable. The equity markets have in the past and may in the future be subject to significant volatility. Liquidity risk Risk of Dilution Operational Risk Nova Eye is an ASX listed entity. Therefore the ability to sell Nova Eye shares will be a dictated trading volumes of the Nova Eye shares at the time of sale. Trading volume itself is a function of the size of Nova Eye and the cumulative investment intentions of all current and possible investors in Nova Eye at any one point in time. Current shareholders in Nova Eye who do not participate in the Offer will have their percentage shareholding in Nova Eye diluted. Investors may also have their investment diluted by future capital raisings or issues of new equity securities by Nova Eye. Nova Eye may issue new equity securities in the future to finance acquisitions or pay down debt which may, under certain circumstances, dilute the value of a shareholder's interest in Nova Eye. Operational risk is the risk of loss resulting from inadequate or failed internal processes, people or systems (including information security systems), or from external events. Nova Eye is exposed to a variety of risks including those arising from process error, fraud, technology failure, security and physical protection, staff skills, workplace safety, compliance, business continuity and crisis management. nova-eye.com | 38#39no NOVAEYE MEDICAL Tom Spurling Managing Director M: +61 417 818 658 E: [email protected] Mark Flynn Investor Relations M: +61 416 068 733 E: [email protected] Kate Hunt Chief Commercial Officer M: +61 404 080 679 E: [email protected]